Akebia Therapeutics Stock Forecast, Price & News

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

Is Akebia Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View analyst ratings for Akebia Therapeutics or view top-rated stocks.

How has Akebia Therapeutics' stock been impacted by Coronavirus?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has decreased by 63.7% and is now trading at $2.52.
View which stocks have been most impacted by COVID-19.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Akebia Therapeutics.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.02. The biopharmaceutical company earned $48.76 million during the quarter, compared to the consensus estimate of $50.09 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 154.75% and a negative net margin of 142.00%. During the same period in the prior year, the company posted ($0.42) EPS.
View Akebia Therapeutics' earnings history.

What price target have analysts set for AKBA?

3 equities research analysts have issued 12 month price targets for Akebia Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Akebia Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:

• John P. Butler, President, Chief Executive Officer & Director (LinkedIn Profile)
• Michel Dahan, Chief Operating Officer & Senior Vice President (LinkedIn Profile)
• David A. Spellman, Chief Financial Officer, Treasurer & Senior VP
• Steven K. Burke, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
• Nicole R. Hadas, Secretary, Senior Vice President & General Counsel

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Akebia Therapeutics' key competitors?

Some companies that are related to Akebia Therapeutics include Erasca (ERAS), Kadmon (KDMN), Travere Therapeutics (TVTX), Enanta Pharmaceuticals (ENTA), Morphic (MORF), IVERIC bio (ISEE), Supernus Pharmaceuticals (SUPN), Dynavax Technologies (DVAX), IGM Biosciences (IGMS), Bicycle Therapeutics (BCYC), Protagonist Therapeutics (PTGX), Verve Therapeutics (VERV), ADC Therapeutics (ADCT), Rocket Pharmaceuticals (RCKT) and ImmunoGen (IMGN).
View all of AKBA's competitors.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.05%), Marshall Wace LLP (3.98%), Geode Capital Management LLC (1.85%), Dimensional Fund Advisors LP (1.20%), Morgan Stanley (0.84%) and Renaissance Technologies LLC (0.54%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics.

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Morgan Stanley, Renaissance Technologies LLC, Citigroup Inc., Millennium Management LLC, Citadel Advisors LLC, and Jump Financial LLC. Company insiders that have sold Akebia Therapeutics company stock in the last year include John P Butler, Michel Dahan, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics or view top insider-selling stocks.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, BlackRock Inc., UBS Group AG, Opaleye Management Inc., Geode Capital Management LLC, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., and Panagora Asset Management Inc..
View insider buying and selling activity for Akebia Therapeutics or or view top insider-buying stocks.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $2.52.

How much money does Akebia Therapeutics make?

Akebia Therapeutics has a market capitalization of $440.90 million and generates $295.31 million in revenue each year. The biopharmaceutical company earns $-383.46 million in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

Akebia Therapeutics employs 380 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

Where are Akebia Therapeutics' headquarters?

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at [email protected], or via fax at 617-871-2099.